EP1578792A2 - Neuescentrosom-assoziiertes protein und dessen anwendungen - Google Patents
Neuescentrosom-assoziiertes protein und dessen anwendungenInfo
- Publication number
- EP1578792A2 EP1578792A2 EP03813937A EP03813937A EP1578792A2 EP 1578792 A2 EP1578792 A2 EP 1578792A2 EP 03813937 A EP03813937 A EP 03813937A EP 03813937 A EP03813937 A EP 03813937A EP 1578792 A2 EP1578792 A2 EP 1578792A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- protein
- seq
- polynucleotide
- asap
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- the protein according to the invention consists of the chain of 13 peptides corresponding to the translation products of 13 of the 14 exons that contains the corresponding gene, the first exon not being translated (see below).
- - Peptide 7 it comprises 24 amino acids corresponding to positions 351 to 374 (SEQ ID NO: 8); - Peptide 8: it comprises 54 amino acids corresponding to positions 375 to 428 (SEQ ID NO: 9);
- sequences SEQ ID NO: 47 to 53 corresponding to mutants of the hASAP protein deleted from the N-terminal part containing the BRCT domain (NdeM: residues 304 -647 (SEQ ID NO: 48); Ndel2: residues 411-647 (SEQ ID NO: 49); Ndel3: residues 478-647 (SEQ ID NO: 50)) or of the C-terminal part containing the MAP domain (CdeM: residues 1 to 477 (SEQ ID NO: 51); Cdel2: residues 1 to 418 (SEQ ID NO: 52); Cdel3: residues 1 to 303 (SEQ ID NO: 53); residues 1 to 421 (SEQ ID NO: 47)).
- said peptide is useful for the production of antibodies specifically recognizing a protein as defined above, preferably recognizing the ASAP protein of sequence SEQ ID NO: 1 or SEQ ID NO: 46 .
- the subject of the invention is also a kit of reagents for the implementation of the methods described above comprising: a) at least one probe or a pair of primers according to the invention; b) the reagents necessary for carrying out a conventional hybridization reaction between said probe or said primers and the nucleic acid of the biological sample; c) the reagents necessary for carrying out an amplification reaction; d) the reagents necessary for the detection and / or the assay of the hybrid formed between said probe and the nucleic acid of the biological sample or of the amplified nucleic acids formed.
- Such substances can be biological macromolecules such as for example a nucleic acid, a lipid, a sugar, a protein, a peptide, a hybrid protein-lipid compound, protein-sugar, peptide-iipid or peptide-sugar, a protein or a peptide to which chemical ramifications have been added or chemical molecules.
- the invention also relates to the polynucleotide, the protein, the antibodies, the vectors or the cells transformed according to the invention, used as medicaments.
- Hoechst 33286 (4A: 63x objective; 4B, 4C, 4D: I00X objective).
- YFP-FIS1 F (5'-AATGTCTGATGAAG I I I I IAGCACC-3 ') (SEQ ID NO: 41)
- the vectors obtained are transfected according to the calcium phosphate technique or more routinely using the jetPE1 process (GDSP10101, Qbiogene) according to the manufacturer's recommendations, in the following cell lines:
- FIG. 5 illustrates the co-location of the human ASAP protein with alpha-tubulin; similarly the murine ASAP protein co-locates with alpha-tubulin.
- RNAi interfering RNA
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0216648A FR2849039B1 (fr) | 2002-12-24 | 2002-12-24 | Nouvelle proteine associee aux centrosomes et ses applications |
| FR0216648 | 2002-12-24 | ||
| PCT/FR2003/003895 WO2004058815A2 (fr) | 2002-12-24 | 2003-12-24 | Proteine associee aux centrosomes et ses applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1578792A2 true EP1578792A2 (de) | 2005-09-28 |
Family
ID=32406499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP03813937A Withdrawn EP1578792A2 (de) | 2002-12-24 | 2003-12-24 | Neuescentrosom-assoziiertes protein und dessen anwendungen |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7402394B2 (de) |
| EP (1) | EP1578792A2 (de) |
| JP (1) | JP4660200B2 (de) |
| AU (1) | AU2003303464A1 (de) |
| CA (1) | CA2511436A1 (de) |
| FR (1) | FR2849039B1 (de) |
| WO (1) | WO2004058815A2 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2789446A1 (en) * | 2010-02-12 | 2011-08-18 | Oncomed Pharmaceuticals, Inc. | Methods for identifying and isolating cells expressing a polypeptide |
| CN115896146B (zh) * | 2022-08-10 | 2026-04-07 | 德州学院 | 荧光蛋白标记的微管蛋白和微管结合蛋白通用型双价载体的构建 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000073801A2 (en) * | 1999-05-28 | 2000-12-07 | Ludwig Institute For Cancer Research | Breast, gastric and prostate cancer associated antigens and uses therefor |
| US6783969B1 (en) * | 2001-03-05 | 2004-08-31 | Nuvelo, Inc. | Cathepsin V-like polypeptides |
-
2002
- 2002-12-24 FR FR0216648A patent/FR2849039B1/fr not_active Expired - Fee Related
-
2003
- 2003-12-24 US US10/540,493 patent/US7402394B2/en not_active Expired - Fee Related
- 2003-12-24 WO PCT/FR2003/003895 patent/WO2004058815A2/fr not_active Ceased
- 2003-12-24 CA CA002511436A patent/CA2511436A1/fr not_active Abandoned
- 2003-12-24 EP EP03813937A patent/EP1578792A2/de not_active Withdrawn
- 2003-12-24 JP JP2004563311A patent/JP4660200B2/ja not_active Expired - Fee Related
- 2003-12-24 AU AU2003303464A patent/AU2003303464A1/en not_active Abandoned
-
2008
- 2008-07-07 US US12/216,510 patent/US20090275024A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2004058815A2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003303464A8 (en) | 2004-07-22 |
| JP4660200B2 (ja) | 2011-03-30 |
| WO2004058815B1 (fr) | 2005-05-06 |
| US20060216710A1 (en) | 2006-09-28 |
| CA2511436A1 (fr) | 2004-07-15 |
| FR2849039B1 (fr) | 2010-10-01 |
| JP2006526387A (ja) | 2006-11-24 |
| WO2004058815A2 (fr) | 2004-07-15 |
| US7402394B2 (en) | 2008-07-22 |
| AU2003303464A1 (en) | 2004-07-22 |
| FR2849039A1 (fr) | 2004-06-25 |
| US20090275024A1 (en) | 2009-11-05 |
| WO2004058815A3 (fr) | 2005-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0868512B9 (de) | Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung | |
| Lim et al. | SPIN90 (SH3 ProteinInteracting with Nck, 90 kDa), an Adaptor Protein That Is Developmentally Regulated during Cardiac Myocyte Differentiation | |
| EP1228091A1 (de) | Membrane-proteine ctl (choline transporter like) die in dem transport der choline involviert sind | |
| WO2001072822A2 (fr) | Genes impliques dans les maladies inflammatoires de l"intestin et leur utilisation | |
| EP0980427B1 (de) | Verwendung von ulip proteinen zur diagnose und therapie von krebs und paraneoplastischen neurologischen syndromen | |
| Ahmady et al. | Identification of a novel muscle A-type lamin-interacting protein (MLIP) | |
| Fritzius et al. | WD‐repeat‐propeller‐FYVE protein, ProF, binds VAMP2 and protein kinase Cζ | |
| EP1578792A2 (de) | Neuescentrosom-assoziiertes protein und dessen anwendungen | |
| EP1259606B1 (de) | Zur steuerung der parkinaktivität brauchbare zusammensetzungen | |
| EP1268790A1 (de) | Erbin kodierendes gen, und ihre anwendung in diagnose und therapie | |
| WO2003040369A2 (fr) | Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments | |
| US20030064372A1 (en) | Gene and sequence variation associated with lipid disorder | |
| US8138307B2 (en) | Parkin interacting polypeptides and methods of use | |
| US20030054418A1 (en) | Gene and sequence variation associated with cancer | |
| EP1257642B1 (de) | Partnern des ptb1 domäne aus fe65, herstellung und verwendungen davon | |
| WO2003025176A2 (fr) | Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments | |
| WO2001085955A1 (fr) | Polypeptide rh116 et ses fragments et polynucleotides codant lesdits polypeptides et applications thérapeutiques | |
| WO2003025177A2 (fr) | Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments | |
| WO2003087153A1 (fr) | Proteine knox-25 en doigt de zinc de type kruppel de souris et son utilisation | |
| WO2001031003A1 (fr) | Clonage, expression et caracterisation d'un gene exprime dans des cellules tumorales et implique dans la regulation de la reponse immune | |
| EP1409675A1 (de) | An der apoptoseregulation beteiligtes gen | |
| WO2003087372A2 (fr) | Facteur de croissance derive d’hepatome et son utilisation | |
| FR2802944A1 (fr) | Sequences nucleotidiques codant pour un polypeptide capable d'interagir avec des proteines des familles p300/cbp et rb |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20050701 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
| DAX | Request for extension of the european patent (deleted) | ||
| 17Q | First examination report despatched |
Effective date: 20080415 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20120703 |